Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. more
Time Frame | KALV | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.42% | -2.27% | -0.57% |
1-Month Return | -16.84% | -3.96% | 1.21% |
3-Month Return | -21.99% | -9.7% | 7.57% |
6-Month Return | -29.12% | -3.37% | 11.45% |
1-Year Return | -12.22% | 3.71% | 28.48% |
3-Year Return | -36.62% | 3.8% | 29.52% |
5-Year Return | -48.67% | 39.78% | 90.66% |
10-Year Return | -88.84% | 106.91% | 203.75% |
Apr '20 | Apr '21 | Apr '22 | Apr '23 | Apr '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 12.69M | 12.69M | - | - | - | [{"date":"2020-04-30","value":100,"profit":true},{"date":"2021-04-30","value":100,"profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Cost of Revenue | 40.19K | 651.00K | 743.00K | 802.00K | 86.17M | [{"date":"2020-04-30","value":0.05,"profit":true},{"date":"2021-04-30","value":0.76,"profit":true},{"date":"2022-04-30","value":0.86,"profit":true},{"date":"2023-04-30","value":0.93,"profit":true},{"date":"2024-04-30","value":100,"profit":true}] |
Gross Profit | 12.65M | 12.04M | (743.00K) | (802.00K) | (86.17M) | [{"date":"2020-04-30","value":100,"profit":true},{"date":"2021-04-30","value":95.17,"profit":true},{"date":"2022-04-30","value":-5.87,"profit":false},{"date":"2023-04-30","value":-6.34,"profit":false},{"date":"2024-04-30","value":-681.17,"profit":false}] |
Gross Margin | 99.68% | 94.87% | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2020-04-30","value":100,"profit":true},{"date":"2021-04-30","value":95.17,"profit":true},{"date":"2022-04-30","value":null,"profit":false},{"date":"2023-04-30","value":null,"profit":false},{"date":"2024-04-30","value":null,"profit":false}] |
Operating Expenses | 53.22M | 57.92M | 96.61M | 110.87M | 54.28M | [{"date":"2020-04-30","value":48,"profit":true},{"date":"2021-04-30","value":52.24,"profit":true},{"date":"2022-04-30","value":87.14,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":48.96,"profit":true}] |
Operating Income | (40.53M) | (57.92M) | (96.61M) | (110.87M) | (140.44M) | [{"date":"2020-04-30","value":-4053300000,"profit":false},{"date":"2021-04-30","value":-5792300000,"profit":false},{"date":"2022-04-30","value":-9661300000,"profit":false},{"date":"2023-04-30","value":-11087100000,"profit":false},{"date":"2024-04-30","value":-14044500000,"profit":false}] |
Total Non-Operating Income/Expense | 13.12M | 12.58M | 15.36M | 20.20M | 9.24M | [{"date":"2020-04-30","value":64.98,"profit":true},{"date":"2021-04-30","value":62.3,"profit":true},{"date":"2022-04-30","value":76.07,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":45.78,"profit":true}] |
Pre-Tax Income | (29.24M) | (46.24M) | (82.34M) | (92.91M) | (135.10M) | [{"date":"2020-04-30","value":-2924000000,"profit":false},{"date":"2021-04-30","value":-4624400000,"profit":false},{"date":"2022-04-30","value":-8233900000,"profit":false},{"date":"2023-04-30","value":-9290700000,"profit":false},{"date":"2024-04-30","value":-13509600000,"profit":false}] |
Income Taxes | (124.00K) | (1.75M) | (13.83M) | (18.05M) | (8.45M) | [{"date":"2020-04-30","value":-12400000,"profit":false},{"date":"2021-04-30","value":-175000000,"profit":false},{"date":"2022-04-30","value":-1382700000,"profit":false},{"date":"2023-04-30","value":-1805400000,"profit":false},{"date":"2024-04-30","value":-845200000,"profit":false}] |
Income After Taxes | (29.12M) | (44.49M) | (68.51M) | (74.85M) | (126.64M) | [{"date":"2020-04-30","value":-2911600000,"profit":false},{"date":"2021-04-30","value":-4449400000,"profit":false},{"date":"2022-04-30","value":-6851200000,"profit":false},{"date":"2023-04-30","value":-7485300000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false}] |
Income From Continuous Operations | (29.12M) | (46.24M) | (82.34M) | (92.91M) | (126.64M) | [{"date":"2020-04-30","value":-2911600000,"profit":false},{"date":"2021-04-30","value":-4624400000,"profit":false},{"date":"2022-04-30","value":-8233900000,"profit":false},{"date":"2023-04-30","value":-9290700000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Net Income | (29.12M) | (44.49M) | (68.51M) | (74.85M) | (126.64M) | [{"date":"2020-04-30","value":-2911600000,"profit":false},{"date":"2021-04-30","value":-4449400000,"profit":false},{"date":"2022-04-30","value":-6851200000,"profit":false},{"date":"2023-04-30","value":-7485300000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false}] |
EPS (Diluted) | (1.64) | (2.40) | (3.36) | (3.36) | (3.40) | [{"date":"2020-04-30","value":-164,"profit":false},{"date":"2021-04-30","value":-240,"profit":false},{"date":"2022-04-30","value":-336,"profit":false},{"date":"2023-04-30","value":-336,"profit":false},{"date":"2024-04-30","value":-340,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
KALV | |
---|---|
Cash Ratio | 6.13 |
Current Ratio | 6.87 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KALV | |
---|---|
ROA (LTM) | -53.94% |
ROE (LTM) | -90.84% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KALV | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.17 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.83 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KALV | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 107.42 |
P/B | 3.21 |
Price/FCF | NM |
EV/R | 76.33 |
EV/Ebitda | NM |
PEG | NM |
Kalvista Pharmaceuticals Inc (KALV) share price today is $8.69
Yes, Indians can buy shares of Kalvista Pharmaceuticals Inc (KALV) on Vested. To buy Kalvista Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KALV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kalvista Pharmaceuticals Inc (KALV) via the Vested app. You can start investing in Kalvista Pharmaceuticals Inc (KALV) with a minimum investment of $1.
You can invest in shares of Kalvista Pharmaceuticals Inc (KALV) via Vested in three simple steps:
The 52-week high price of Kalvista Pharmaceuticals Inc (KALV) is $16.88. The 52-week low price of Kalvista Pharmaceuticals Inc (KALV) is $8.48.
The price-to-earnings (P/E) ratio of Kalvista Pharmaceuticals Inc (KALV) is
The price-to-book (P/B) ratio of Kalvista Pharmaceuticals Inc (KALV) is 3.21
The dividend yield of Kalvista Pharmaceuticals Inc (KALV) is 0.00%
The market capitalization of Kalvista Pharmaceuticals Inc (KALV) is $449.21M
The stock symbol (or ticker) of Kalvista Pharmaceuticals Inc is KALV